Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Herceptin with XELOX in HER-2 positive gastric cancer with liver metastasis
NCT02380131Phase 4Unknown
- Sponsor
- Hebei Medical University
- Start
- Feb 2013
- Primary completion
- Dec 2017
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of trastuzumab in gastric cancer (GC) and liver metastasis (3 arms), sponsored by Hebei Medical University. Primary endpoint: Progression-Free Survival at 2 years. Status: unknown.
02
Drugs
03
Conditions
gastric cancer (GC)liver metastasis
Beyond the preview
Go deeper on NCT02380131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02380131.